Mosaic Biosciences and Uniquity Bio team up on biologics discovery

Mosaic Biosciences and Uniquity Bio said Aug. 5 they have formed a strategic collaboration to advance biologic drug candidates for immunology and inflammation programs. The deal pairs Mosaic’s platform-agnostic discovery capabilities with Uniquity Bio’s clinical-stage pipeline as both companies push toward faster, more precise development.

Why it matters: - The collaboration is designed to speed up biologics discovery for programs aimed at diseases with major unmet need. - Mosaic Biosciences adds discovery and lead-optimization capabilities. - Uniquity Bio adds a clinical-stage immunology and inflammation pipeline. - The partnership could help move higher-quality biologic candidates into development with less dependence on a single discovery platform.

What happened: - Mosaic Biosciences announced a strategic collaboration with Uniquity Bio on Aug. 5, 2026. - Mosaic Biosciences is a full-service biologics discovery contract research organization based in Boulder, Colorado. - Uniquity Bio is a clinical-stage drug development company focused on immunology and inflammation. - The companies said the collaboration combines Mosaic’s platform-agnostic discovery model with Uniquity Bio’s scientific rigor and operational agility.

The details: - Mosaic specializes in biologics discovery and lead optimization using platform-agnostic approaches. - Mosaic’s integrated capabilities include in vitro display, single B cell methods, transgenic animal platforms and AI-enabled screening approaches. - Uniquity Bio develops therapeutic programs with an emphasis on high-potential medicines for indications with significant unmet need. - Uniquity Bio’s lead asset is solrikitug, a highly potent monoclonal antibody targeting TSLP in multiple respiratory and gastrointestinal indications. - Uniquity Bio is backed by Blackstone Life Sciences. - The company was built by biopharmaceutical executives with a track record in drug development. - Mosaic’s CEO Jean-Pierre Wery said the company was built on the belief that discovery strategy should be tailored to the biology, not the platform. - Uniquity Bio Vice President of Translational Medicine Kiyomi Komori said Mosaic’s scientific depth and strategic partnership model go beyond traditional CRO relationships. - Mosaic directs readers to more information. - Uniquity Bio directs readers to the company website. - Mosaic’s LinkedIn page is available here.

Between the lines: - The collaboration reflects a broader industry push to pair flexible discovery platforms with programs already moving toward the clinic. - Mosaic appears to be positioning itself as a science-driven partner rather than a standard outsourced research vendor. - Uniquity Bio is signaling that external discovery expertise can support pipeline advancement without sacrificing speed or quality.

What's next: - The companies did not announce financial terms, timelines or specific programs covered by the collaboration. - Future work likely centers on advancing biologic candidates through discovery and lead optimization for immunology and inflammation targets. - Uniquity Bio will continue developing solrikitug across respiratory and gastrointestinal indications.

The bottom line: - Mosaic Biosciences and Uniquity Bio are joining forces to pair flexible biologics discovery with a clinical-stage pipeline, betting that a platform-agnostic approach can accelerate next-generation medicines.